



DEPOSITARY RECEIPTS

NEW DR ANNOUNCEMENT

July 31, 2014

Therapix Biosciences Ltd.

Therapix Biosciences is a pharmaceutical group based in Israel. The Company is engaged in the development of improved vaccines and immunotherapeutics. The Company's product offering includes: oral anti-CD3 monoclonal antibody (MAb), an immunotherapeutic for treating inflammatory and autoimmune diseases, such as nonalcoholic steatohepatitis, Hepatitis C, and ulcerative colitis; a Group-common Pneumococcal Vaccine based on surface proteins that are highly conserved among pneumococcal strains; BBS MAb, an immunotherapeutic for Alzheimer's disease; and an Adjuvant-Delivery platform, VaxiSome, which serves both as a potent adjuvant for stimulating enhanced immune responses via the Th1 and Th2 pathways.

Effective Date:	July 31, 2014
Country of Incorporation:	Israel
Exchange:	OTC
Type of ADR Program:	Sponsored - Level I
Ticker Symbol:	THXBY
CUSIP Number:	88339A104
Ratio (DR:ORD):	1 : 20
Underlying Share Description:	Ordinary
Industry Classification:	Pharma. & Biotech.
Custodian(s) :	Bank Hapoalim B.M. Bank Leumi Le-Israel

To learn more about ADRs and issuer programs, please call our marketing desks:

New York

Melissa Sobolewski/Ravi Davis
Ardesk@bnymellon.com
Tel: 212 815 2267

Hong Kong

Herston Powers
Vice President
herston.powers@bnymellon.com
Tel: 852 2840 9868

London

Damon Rowan
Vice President
damon.rowan@bnymellon.com
Tel: 442071637511

Depository Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon and are subject to investment risks including possible loss of principal amount invested.

This announcement and the information contain herein is provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this information. We provide no advice or recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. An offering is made by means of a prospectus only. BNY Mellon is regulated by the FSA.